Key facts
- Eli Lilly's retatrutide showed significant weight loss in Phase 3 trials.
- Participants lost an average of 70.3 lbs over 80 weeks on retatrutide.
- Retatrutide also showed promise for knee osteoarthritis.
- Retatrutide also showed promise for obstructive sleep apnea.
- Real-world data compared semaglutide 2 mg and tirzepatide.
- Adults with type 2 diabetes were studied.
- Semaglutide 2 mg patients achieved comparable HbA1c levels to tirzepatide patients.
- Semaglutide 2 mg patients achieved greater weight loss than tirzepatide patients.
- The semaglutide data analyzed patients whose dose increased from 1 mg to 2 mg.
Eli Lilly's investigational drug retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon, has demonstrated substantial weight loss in Phase 3 trials. Participants in the trial lost an average of 70.3 pounds over an 80-week period. Beyond weight reduction, retatrutide also showed promising results in addressing other health conditions. The drug demonstrated potential efficacy in treating knee osteoarthritis and obstructive sleep apnea, suggesting a broader therapeutic application.